Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

11.72 -0.05 (-0.42%)
Streaming Delayed Price Updated: 3:53 PM EDT, Jul 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dr. Reddy's Laboratories Ltd Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Is NYSE:RDY suited for quality investing? ↗
Exploring DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)'s quality characteristics. 
Via Chartmill
News headline image
Top 5 Health Care Stocks That May Fall Off A Cliff ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Should you consider NYSE:RDY for quality investing? ↗
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) may be suited for quality investing, we'll explore why in this article. 
Via Chartmill
News headline image
Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
News headline image
Chart Of The Day: What's Cooking At Dr. Reddy's Lab ↗
100% technical buy signals 12 new highs and up 10.76% in the last month 38.40+ Weighted Alpha 
Via Talk Markets
News headline image
Dr. Reddy’s Q1 FY24 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Why Are Journey Medical Shares Trading Lower Today? ↗
Journey Medical Corporation (NASDAQ: DERM) shares are trading lower after the company announced topline results from the two Phase 3 trials, evaluating Minocycline Hydrochloride Modified Release... 
Via Benzinga
News headline image
Drugmaker GSK: Becoming a Healthier Value Stock
Up more than 25% in the last nine months, U.K. pharmaceutical company GSK PLC is slowly regaining favor with investors after the GSK lawsuit. 
Via MarketBeat
Topics Lawsuit
News headline image
Why Are Journey Medical Shares Trading Higher Today ↗
Journey Medical Corporation (NASDAQ: DERM) announced topline data from the Phase 1 clinical trial assessing the impact of DFD-29 on the  
Via Benzinga
News headline image
Dr. Reddy’s Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
The 3 Most Undervalued Value Stocks to Buy in June 2023 ↗
One positive aspect about broader market challenges is the rising opportunity in the best undervalued value stocks for June. 
Via InvestorPlace
News headline image
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC ↗
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr.... 
Via Talk Markets
News headline image
Dr. Reddy’s Q4 & FY23 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories Announces the Launch of Treprostinil Injection in the U.S.
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
News headline image
Why Aditxt Shares Are Surging Today ↗
Aditxt, Inc. (NASDAQ: ADTX) stock is surging Thursday as it expands its portfolio to include innovative therapies for infectious diseases. 
Via Benzinga
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) Making Surprising Moves in Wednesday Session
Via Investor Brand Network
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) Sets New 52-Week High in Monday Session
Via Investor Brand Network
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
By David Willey, Benzinga 
Via TheNewswire.com
News headline image
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development 
Via News Direct
News headline image
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development ↗
Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India. 
Via Benzinga
News headline image
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302 
Via News Direct
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
By Kenneth Adams, Benzinga 
Via TheNewswire.com
News headline image
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy's Laboratories To License And Commercialize COYA 302 ↗
Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced a worldwide agreement with Dr. Reddy’s Laboratories Limited. 
Via Benzinga
News headline image
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Dr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Generic Prescription Deal ↗
 
Via Benzinga
News headline image
Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy’s included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global’s Sustainability Yearbook for the 3rd year
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
The 3 Most Undervalued Stocks in India for Your February Buy List ↗
These are a few of the top undervalued stocks in India, providing investors with exposure to strong growth outlooks in the coming years. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.